Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12.

From:
Department for International Development
Published
1 January 2004
Country:
United States
Document Type:
Journal Article
Theme:
Health
Authors:
Sha, B.E., Onorato, M., Bartlett, J.A., Bosch, R.J., Aga, E., Nokta, M., Adams, E.M., Li, X.D., Eldridge, J., Pollard, R.B.

Abstract

We examined the safety and immunogenicity of a human leukocyte antigen-based HIV envelope polyvalent synthetic peptide vaccine, C4-V3, alone and in combination with subcutaneous IL-12 in nine HIV-infected patients. Lymphocyte proliferative responses increased threefold or more to all four peptides at two consecutive post-immunization timepoints for four individuals. Three responders had received IL-12, suggesting a possible adjuvant effect of IL-12. Transient mild injection site reactions (7/9) and systemic symptoms (3/9) occurred.

Citation

Sha, B.E.; Onorato, M.; Bartlett, J.A.; Bosch, R.J.; Aga, E.; Nokta, M.; Adams, E.M.; Li, X.D.; Eldridge, J.; Pollard, R.B. Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12. AIDS (2004) 18 (8) 1203-1216.

Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12.

Updates to this page

Published 1 January 2004
Contents